$8.9M Bioness Stockholder Settlement, Were You Cut Out of a Fair Price When They Sold the Company? Claim Before April 24

Bioness Inc. minority stockholders filed a class action in Delaware’s Court of Chancery alleging they were shortchanged when the orthopedic device company sold to Bioventus Inc. for $110 million in March 2021. Plaintiffs argued the deal was engineered to favor Bioness’s controlling creditor at the expense of minority stockholders. A proposed $8,900,000 settlement now awaits court approval, with a final hearing scheduled for May 8, 2026.

Quick Facts

Field	Detail
Settlement Amount	$8,900,000
Claim Deadline	TBD (check BionessStockholderSettlement.com)
Who Qualifies	Record and beneficial holders of Bioness, Inc. common stock as of March 30, 2021
Payout Per Person	Pro rata share of net settlement fund
Proof Required	TBD
Settlement Status	Proposed — Final Hearing May 8, 2026
Administrator	Epiq Systems, Inc.
Official Website	BionessStockholderSettlement.com

Where Things Stand Right Now

• The Court of Chancery of Delaware set the final settlement approval hearing for May 8, 2026, at 1:30 p.m. before the Honorable Bonnie W. David in Georgetown, Delaware.
• Objections to the settlement must be received by Plaintiffs’ Counsel and Defendants’ Counsel no later than April 24, 2026.
• If the court approves the settlement, Epiq Systems will distribute the net settlement fund on a pro rata basis — meaning your payout depends on how many stockholders file valid claims.

The $110 Million Sale That Minority Stockholders Said Wasn’t Fair

An Israeli tech investor opened a 10-count Delaware Chancery Court class challenge to Bioness’s $110 million acquisition by Bioventus Inc. in February 2022, alleging a low-ball, controller-orchestrated fire sale mainly arranged to benefit both the company’s largest creditor and its buyer.

Bioness makes medical devices — specifically electrical stimulation devices used in physical rehabilitation. The company was acquired by Bioventus, a surgical orthobiologics company, in March 2021. Minority stockholders alleged they had no real say in the sale and that the controlling creditor structured the deal to serve its own financial interests first.

Delaware’s Court of Chancery trimmed down the proposed class action in April 2023, but the remaining claims moved forward. After nearly four years of litigation, the parties agreed to the $8.9 million cash settlement in January 2026.

You Were a Bioness Stockholder on March 30, 2021 — Here’s What That Means

The settlement class covers all record and beneficial holders of Bioness, Inc. common stock as of March 30, 2021, together with their heirs, assigns, transferees, and successors-in-interest.

To break that down plainly:

• You may qualify if you held Bioness, Inc. common stock on the record date of March 30, 2021 — the date tied to the company’s sale to Bioventus.
• You may qualify if you held shares beneficially (meaning through a brokerage or investment account, even if the shares were registered in the broker’s name).
• You may qualify if you are the heir, transferee, or successor of someone who held qualifying shares on that date and did not receive their rightful recovery.
• You likely do not qualify if you held Bioventus Inc. stock (the acquiring company) rather than Bioness Inc. stock. These are two separate cases — a different $15.25 million Bioventus securities settlement covers Bioventus investors who suffered losses during 2021–2022.

If you’re unsure which company’s stock you held, check your brokerage records for March 30, 2021. Bioness Inc. was a private medical device company — not publicly traded on a stock exchange — so shares were held primarily by institutional and accredited investors, not retail shareholders.

Related article: $2.88M Amica Kept Your Arizona Insurance Benefits Low — Here’s What You May Be Owed, Claim before the May 21

$8.9 Million Split Among the Class — What Your Share Could Look Like

If the settlement receives court approval and becomes effective, the net settlement fund will be distributed on a pro rata basis to class members in accordance with the proposed Plan of Allocation.

“Pro rata” means the $8.9 million — minus attorneys’ fees, litigation expenses, and Epiq’s administrative costs — gets divided proportionally based on the size of each class member’s verified stockholding. Stockholders with larger positions will receive proportionally larger payments.

The exact per-share or per-stockholder payout amount is TBD until the court approves the Plan of Allocation and the total number of valid claimants is known. The official notice available at BionessStockholderSettlement.com contains the full Plan of Allocation details.

Four Steps to Submit Your Claim

Step 1 — Visit the official settlement website at BionessStockholderSettlement.com and download the full Notice, which contains claim submission instructions.

Step 2 — Contact the settlement administrator directly if you did not receive a mailed notice: call 1-877-269-4873 or email [email protected].

Step 3 — Complete your Proof of Claim form with your stockholder details, including confirmation of Bioness, Inc. stock held as of March 30, 2021.

Step 4 — Submit your completed claim form by mail to: Bioness Stockholder Settlement, c/o Epiq Systems, Inc., P.O. Box 5450, Portland, OR 97228-5450.

Estimated time to complete: 15–20 minutes (longer if you need to locate brokerage records).

Four Years to a Settlement — The Timeline

Milestone	Date
Bioness acquisition by Bioventus closes	March 2021
Class action filed in Delaware Court of Chancery	February 2022
Court of Chancery partially dismisses claims	April 2023
Stipulation of Settlement signed	January 29, 2026
Summary Notice issued to class members	March 2, 2026
Objection / Opt-Out Deadline	April 24, 2026
Final Approval Hearing	May 8, 2026
Claim Filing Deadline	TBD — check BionessStockholderSettlement.com
Expected Payment Date	TBD — post final approval

Frequently Asked Questions

Do I need a lawyer to file a claim?

 No. Class members can submit a claim directly through the settlement administrator without hiring an attorney. Plaintiffs’ Counsel — Levi & Korsinsky, LLP and Ashby & Geddes, P.A. — already represents the class as a whole. You may consult your own attorney, but you are not required to.

Is this settlement legitimate? 

Yes. The settlement is pending in the Court of Chancery of the State of Delaware under Case No. 2022-0130-BWD, with a final approval hearing scheduled before the Honorable Bonnie W. David on May 8, 2026. The settlement administrator is Epiq Systems, Inc., a nationally recognized legal services firm. The official website is BionessStockholderSettlement.com.

When will I receive my payment? 

Payment timing is TBD. The court must first approve the settlement at the May 8, 2026 hearing. After final approval, Epiq Systems processes and verifies all claims before distributing funds. Stockholder settlements of this type typically distribute payments within 6–12 months of final court approval.

What if I missed the claim deadline?

 The claim deadline has not yet been published. Check BionessStockholderSettlement.com for updates. If the deadline passes before you file, late claims are generally not accepted unless the court grants an exception. Contact Epiq Systems at 1-877-269-4873 as soon as possible if you believe you qualify.

Will this settlement payment affect my taxes? 

Possibly. Settlement proceeds from stockholder class actions may be treated as capital gains or ordinary income depending on your individual tax situation and the nature of your original investment. Consult a tax professional before filing your claim if you have questions about the tax treatment of your potential recovery.

I held Bioventus stock, not Bioness stock — am I in the wrong settlement?

 Yes, this is a different case. This $8.9 million settlement covers Bioness, Inc. stockholders as of March 30, 2021. If you purchased Bioventus Class A common stock between February 11, 2021, and November 21, 2022, a separate $15.25 million Bioventus securities settlement existed — though its December 2, 2024 claim deadline has already passed.

Can I object to the settlement instead of accepting it? 

Yes. Any class member who disagrees with the settlement terms, the Plan of Allocation, or the attorneys’ fee request may file a written objection. Objections must be filed with the Register in Chancery and delivered to Plaintiffs’ Counsel and Defendants’ Counsel so they are received no later than April 24, 2026. The full objection instructions appear in the official Notice at BionessStockholderSettlement.com.

What exactly did the defendants allegedly do wrong? 

Plaintiffs alleged that Bioness’s controlling creditor and certain board members structured the $110 million sale to Bioventus to benefit themselves, not minority stockholders. The lawsuit claimed that minority shareholders received less than fair value for their shares because insiders prioritized their own debt recovery over maximizing the sale price for all stockholders.

Sources & References

• Official Settlement Website: BionessStockholderSettlement.com
• Court Filing / Official Notice: PR Newswire — Levi & Korsinsky Summary Notice, March 2, 2026
• Law360 Case Report: Bioness $110M Sale Suit Heads to $8.9M Deal, January 16, 2026

Last Updated: March 31, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Legal claims and outcomes depend on specific facts and applicable law. For advice regarding a particular situation, consult a qualified attorney.